HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Press Releases Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:35 18/07/2025 BST			5-day change	1st Jan Change
36.05 ^HKD	+4.49%		+14.44%	+108.62%

07-17	Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$31.82 From HK$25.64, Keeps at Neutral	MT
06-04	Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing	CI

Press Releases

Hansoh Pharma \| Aumolertinib: Approved by UK’s MHRA for the Treatment of NSCLC — Marking the First Overseas Launch of China-Developed EGFR-TKI	06-05	PU
Hansoh Pharmaceutical : PHARMA GRANTS REGENERON AN EXCLUSIVE LICENSE RIGHTS TO ITS INVESTIGATIONAL DUAL GLP-1/GIP RECEPTOR AGONIST HS-20094	06-02	PU
Hansoh Pharmaceutical : PHARMA ANNOUNCES THE THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE(INEBILIZUMAB INJECTION) ACCEPTED BY NMPA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS	05-31	PU
Hansoh Pharmaceutical : Pharma \| Ameile's fourth indication approved for marketing, targeting post-operative adjuvant therapy for EGFR mutation-positive non-small cell lung cancer	05-09	PU
Hansoh Pharmaceutical : 2024环境、社会及管治报告	04-27	PU
Hansoh Pharmaceutical : ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024	04-27	PU
Hansoh Pharmaceutical : PHARMA RECEIVES THE CLINICAL TRIAL APPROVAL FROM NMPA FOR HS-10529 in advanced solid tumors	04-15	PU
2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference	24/01/24	AQ
Hansoh Pharmaceutical Group Co., Ltd. - The 24th China Patent Awards Ceremony was held, and Hansoh Pharma's Ametinib patent was awarded the China Patent Gold Award	19/10/23	AQ
Hansoh Pharmaceutical's Saint Relais is the first batch to be shipped nationwide, bringing a safe and long-lasting new option to CKD patients with renal anemia	25/09/23	AQ
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China	20/07/23	AQ
KiOmed Pharma and Hansoh Pharma Announce License Agreement for KioMedinevsone in China's Mainland, Macau and Taiwan	27/09/22	AQ
Hansoh Pharmaceutical : FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021	29/03/22	PU
Hansoh Pharmaceutical : Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China	12/10/21	AQ
SCYNEXIS : Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)	14/09/21	AQ
SCYNEXIS : Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)	13/09/21	AQ
Hansoh Pharmaceutical : Accelerate Benefits for Hepatitis B Patients! Hansoh Pharma's New Class 1 Drug Hengmu (Tenofovir Amibufenamide Tablets) Prescribed for the First Time in China	06/07/21	AQ
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF AMEILE IN FIRST LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	13/05/21	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FDA TENTATIVE APPROVAL OF "BORTEZOMIB FOR INJECTION"	10/05/21	PU
Hansoh Pharmaceutical : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 3, 2021	27/04/21	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "LENALIDOMIDE CAPSULE"	01/04/21	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "EMPAGLIFLOZIN TABLETS"	31/07/20	PU
Hansoh Pharmaceutical : INSIDE INFORMATION - LICENSE AGREEMENT WITH EQRX	23/07/20	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Hansoh Pharmaceutical Group Company Limited : Regulator grants breakthrough-therapy status to lung cancer drug

December 03, 2024 at 05:32 pm